Chimeric Endolysin Polypeptide for Staphylococcus Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current endolysins targeting Staphylococcus species face challenges such as low enzyme activity and stability, making them less effective and difficult to produce in large quantities, which limits their antimicrobial activity and specificity.
Innovation Solution
A novel chimeric endolysin polypeptide with at least 82% sequence identity to a benchmark endolysin, comprising specific domains and a linker, is developed to enhance lytic activity against Staphylococcus species, including Staphylococcus aureus, while maintaining specificity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional endolysins are used to target Staphylococcus species, then they provide antimicrobial activity, but they exhibit low enzyme activity and stability
Solution Approach 1:
The patent combines multiple endolysin domains (M23 domain, CHAP domain, and SH3b domain) into a single chimeric polypeptide structure. This merging of functional domains creates a synergistic effect where the M23 domain provides peptidase activity, the CHAP domain provides amidohydrolase activity, and the SH3b domain provides cell wall binding specificity, collectively enhancing both stability and antimicrobial efficacy compared to conventional single-domain endolysins
Solution Approach 2:
The chimeric endolysin polypeptide represents a composite protein structure integrating different enzymatic domains with distinct functions. The M23 peptidase domain, CHAP amidohydrolase domain, and SH3b cell-wall-binding domain are fused to create a multi-functional composite molecule that achieves superior enzyme activity and stability compared to individual domains or conventional endolysins
2Ease of manufacture
If conventional endolysins are used, then they can be produced, but production in large quantities is difficult
Solution Approach 1:
The chimeric endolysin is designed as a modular polypeptide with distinct functional domains (M23, CHAP, SH3b) separated by linker regions. This segmentation allows for optimized expression in E. coli systems, where each domain can be independently folded and stabilized, facilitating large-scale production while maintaining protein stability and activity
3Productivity
If broad-spectrum disinfectants or antibiotics are used, then antimicrobial activity is achieved, but beneficial microflora are killed and antibiotic resistance spreads
Solution Approach 1:
The chimeric endolysin incorporates an SH3b cell-wall-binding domain that provides highly specific recognition of Staphylococcus aureus cell wall structures. This localized binding specificity ensures that the antimicrobial activity is directed only at S. aureus cells, leaving beneficial microflora unaffected and eliminating the selection pressure that drives antibiotic resistance development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel endolysin polypeptide demonstrates significantly increased lytic activity against Staphylococcus aureus, with a 10-fold increase in colony-forming unit reduction at certain concentrations, while showing no activity against other beneficial bacteria, thus improving antimicrobial efficacy and stability.
Implementation Method 1
Peptidoglycan hydrolases (PGHs) can cleave specific bonds within the peptidoglycan (PG) network of bacteria
Implementation Method 2
Endolysins are highly specific, phage-derived PGHs
Data Source
AI summary
The invention relates to the field of antibacterial polypeptides, specifically to the field of antibacterial polypeptides having lytic activity for Staphylococcus. The invention relates to a novel chimeric endolysin polypeptide specifically targeting a Staphylococcus cell. The invention further relates to the use of said chimeric endolysin polypeptide as a disinfectant, as an antimicrobial cosmetic, for detection, such as in a diagnostic application and for medical use, such as for treating an individual suffering from a condition associated with a Staphylococcus infection.